In the following video, Fool analysts David Williamson and Austin Smith look at the management running small biotech Dendreon (NASDAQ: DNDN ) .
Former CEO Mitch Gold deserves a lot of the credit for getting prostate cancer drug Provenge approved, but also a lot of the blame for the delays in getting the product launched, David says.
While many like to blame Wall Street for hyping Dendreon, the hype originated with the company, David says. Today, the numbers Gold expected for the drug appear comically high.
He also oversaw a manufacturing expansion that led to chronic oversupply, while his sales team failed to persuade doctors to use the drug, David says.
New CEO John Johnson came in with a strong reputation as the head of Imclone Systems, which eventually became part of Eli Lilly. David says he seems to understand the challenges facing Provenge.
His work to restructure the company is also a step in the right direction, David says.
Can the new CEO right Dendreon's ship? The company's run over the past four years has seen sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine, Provenge, became a lightning rod for debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand-new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.